Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
PaperCitations, authors & open-access status
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 528 citations, 2020 year and closed oa status.
528
Citations
2020
Year
closed
OA Status